Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Liver Cirrhosis

  Free Subscription

Articles published in Dig Dis

Retrieve available abstracts of 45 articles:
HTML format

Single Articles

    April 2021
  1. MEYER JJ, Dreyhaupt J, Schwerdel D, Ettrich TJ, et al
    Blood-based targeted metabolomics discriminate patients with alcoholic liver cirrhosis from those with non-cirrhotic liver damage: an explorative study.
    Dig Dis. 2021 Apr 16. pii: 000516488. doi: 10.1159/000516488.

    November 2020
  2. WEN M, Men R, Fan X, Shen Y, et al
    Worse Response to Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients with Autoimmune Hepatitis Features.
    Dig Dis. 2020 Nov 25. pii: 000513331. doi: 10.1159/000513331.
    PubMed     Abstract available

  3. IDILMAN R, Aydogan M, Oruncu MB, Kartal A, et al
    Dig Dis. 2020 Nov 3. pii: 000512746. doi: 10.1159/000512746.
    PubMed     Abstract available

    August 2020
  4. MOON AM, Watkins SE, Lok AS, Firpi-Morell RJ, et al
    Opioid Use is More Common in Non-Alcoholic Fatty Liver Disease Patients with Cirrhosis, Higher Body Mass Index and Psychiatric Disease.
    Dig Dis. 2020 Aug 24. pii: 000511074. doi: 10.1159/000511074.
    PubMed     Abstract available

  5. RAMRAKHIANI NS, Le M, Yeo YH, Le A, et al
    Validity of International Classification of Diseases, 10th Revision, Codes for Cirrhosis.
    Dig Dis. 2020 Aug 19. pii: 000510981. doi: 10.1159/000510981.
    PubMed     Abstract available

    May 2020
  6. KIMURA N, Tsuchiya A, Oda C, Kimura A, et al
    Visceral adipose tissue index and hepatocellular carcinoma are independent predictors of outcome in patients with cirrhosis having endoscopic treatment for esophageal varices.
    Dig Dis. 2020 May 25. pii: 000508867. doi: 10.1159/000508867.
    PubMed     Abstract available

    March 2020
  7. MILOVANOVIC T, Popovic D, Stojkovic Lalosevic M, Dumic I, et al
    Quality Of Life in Patients With Primary Biliary Cholangitis: A Single Center Experience in Serbia.
    Dig Dis. 2020 Mar 6. pii: 000506980. doi: 10.1159/000506980.
    PubMed     Abstract available

    December 2019
  8. ARORA MS, Kaushik R, Ahmad S, Kaushik RM, et al
    Profile of Acute Kidney Injury in Patients with Decompensated Cirrhosis at a Tertiary-Care Center in Uttarakhand, India.
    Dig Dis. 2019 Dec 12:1-9. doi: 10.1159/000504836.
    PubMed     Abstract available

    June 2019
  9. UOJIMA H, Hidaka H, Tanaka Y, Wada N, et al
    Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis.
    Dig Dis. 2019 Jun 19:1-8. doi: 10.1159/000501267.
    PubMed     Abstract available

  10. FACCIORUSSO A, Buccino VR, Del Prete V, Antonino M, et al
    Cirrhosis Is a Predictor of Adverse Events in Endoscopic Ultrasound Fine-Needle Aspiration: A Propensity-Score Analysis.
    Dig Dis. 2019 Jun 18:1-8. doi: 10.1159/000501268.
    PubMed     Abstract available

  11. MANZHALII E, Virchenko O, Falalyeyeva T, Moiseienko V, et al
    Hepatic Encephalopathy Aggravated by Systemic Inflammation.
    Dig Dis. 2019 Jun 6:1-9. doi: 10.1159/000500717.
    PubMed     Abstract available

    January 2019
  12. KIDA Y
    Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Dig Dis. 2019 Jan 9:1-8. doi: 10.1159/000494438.
    PubMed     Abstract available

  13. AZUMA S, Asahina Y, Kakinuma S, Azuma K, et al
    Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Dig Dis. 2019 Jan 9:1-8. doi: 10.1159/000493580.
    PubMed     Abstract available

  14. SHIRIN D, Peleg N, Sneh-Arbib O, Cohen-Naftaly M, et al
    The Pattern of Elevated Liver Function Tests in Nonalcoholic Fatty Liver Disease Predicts Fibrosis Stage and Metabolic-Associated Comorbidities.
    Dig Dis. 2019;37:69-76.
    PubMed     Abstract available

    September 2018
  15. GOTTLIEB A, Kottmann M, Manka P, Bedreli S, et al
    How to Define Acute Liver Failure Patients with Pre-Existing Liver Disease without Signs of Cirrhosis.
    Dig Dis. 2018 Sep 18:1-8. doi: 10.1159/000492869.
    PubMed     Abstract available

    May 2018
  16. TAJIRI K, Tokimitsu Y, Ito H, Atarashi Y, et al
    Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Dig Dis. 2018 May 31:1-8. doi: 10.1159/000489258.
    PubMed     Abstract available

    January 2018
  17. HUANG XW, Liao B, Huang Y, Liang JY, et al
    Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable?
    Dig Dis. 2018 Jan 19. pii: 000486196. doi: 10.1159/000486196.
    PubMed     Abstract available

  18. BAI L, Jin W, Kong M, Zhang X, et al
    Injury Resistance in the Setting of Liver Fibrosis Is Accompanied by the Inhibition of High-Mobility Group Box-1 Translocation and Release.
    Dig Dis. 2018;36:167-176.
    PubMed     Abstract available

  19. PAN X, Han Y, Zou T, Zhu G, et al
    Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis.
    Dig Dis. 2018;36:427-436.
    PubMed     Abstract available

    November 2017
  20. SHI L, Zhang X, Li J, Bai X, et al
    Favorable Effects of Endoscopic Ligation Combined with Drugs on Rebleeding and Mortality in Cirrhotic Patients: A Network Meta-Analysis.
    Dig Dis. 2017 Nov 21. doi: 10.1159/000484082.
    PubMed     Abstract available

    March 2017
  21. DI PASCOLI M, Ceranto E, De Nardi P, Donato D, et al
    Hospitalizations Due to Cirrhosis: Clinical Aspects in a Large Cohort of Italian Patients and Cost Analysis Report.
    Dig Dis. 2017 Mar 1. doi: 10.1159/000458722.
    PubMed     Abstract available

    January 2017
  22. POSE E, Cardenas A
    Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention.
    Dig Dis. 2017;35:402-410.
    PubMed     Abstract available

  23. HEGADE VS, Jones DE, Hirschfield GM
    Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Dig Dis. 2017;35:267-274.
    PubMed     Abstract available

  24. WONG LL, Hegade VS, Jones DEJ
    What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Dig Dis. 2017;35:359-366.
    PubMed     Abstract available

  25. IREDALE JP, Pellicoro A, Fallowfield JA
    Liver Fibrosis: Understanding the Dynamics of Bidirectional Wound Repair to Inform the Design of Markers and Therapies.
    Dig Dis. 2017;35:310-313.
    PubMed     Abstract available

  26. KOBAYASHI N, Kumada T, Toyoda H, Tada T, et al
    Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
    Dig Dis. 2017;35:521-530.
    PubMed     Abstract available

  27. YADA N, Tamaki N, Koizumi Y, Hirooka M, et al
    Diagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear Wave Imaging in Patients with Liver Disease.
    Dig Dis. 2017;35:515-520.
    PubMed     Abstract available

    June 2016
  28. FITZ JG
    Hepatology after Hepatitis C.
    Dig Dis. 2016;34:603-606.
    PubMed     Abstract available

    January 2016
  29. CHISHINA H, Hagiwara S, Nishida N, Ueshima K, et al
    Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Dig Dis. 2016;34:659-664.
    PubMed     Abstract available

  30. SCORLETTI E, Byrne CD
    Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.
    Dig Dis. 2016;34 Suppl 1:11-8.
    PubMed     Abstract available

  31. MAHLI A, Hellerbrand C
    Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:32-9.
    PubMed     Abstract available

  32. DE ALWIS NM, Anstee QM, Day CP
    How to Diagnose Nonalcoholic Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:19-26.
    PubMed     Abstract available

  33. YADA N, Sakurai T, Minami T, Arizumi T, et al
    Prospective Risk Analysis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C by Ultrasound Strain Elastography.
    Dig Dis. 2016;34:650-653.
    PubMed     Abstract available

  34. WU T, Wang P, Zhang T, Zheng J, et al
    Comparison of Two-Dimensional Shear Wave Elastography and Real-Time Tissue Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B.
    Dig Dis. 2016;34:640-649.
    PubMed     Abstract available

  35. NISHIDA N, Kono M, Minami T, Chishina H, et al
    Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2.
    Dig Dis. 2016;34:632-639.
    PubMed     Abstract available

  36. SUGIMOTO K, Kim SK, Kim SR, Kobayashi M, et al
    Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2.
    Dig Dis. 2016;34:627-631.
    PubMed     Abstract available

  37. HAGIWARA S, Nishida N, Watanabe T, Sakurai T, et al
    Outcome of Asunaprevir/Daclatasvir Combination Therapy for Chronic Liver Disease Type C.
    Dig Dis. 2016;34:620-626.
    PubMed     Abstract available

  38. GALLE PR
    Extended Abstract: Management of Liver Cancer.
    Dig Dis. 2016;34:438-9.
    PubMed     Abstract available

  39. WEISKIRCHEN R, Tacke F
    Liver Fibrosis: From Pathogenesis to Novel Therapies.
    Dig Dis. 2016;34:410-22.
    PubMed     Abstract available

    Novel Aspects in the Management of Cholestatic Liver Diseases.
    Dig Dis. 2016;34:340-6.
    PubMed     Abstract available

    Variant Syndromes of Autoimmune Liver Diseases: Classification, Diagnosis and Management.
    Dig Dis. 2016;34:334-9.
    PubMed     Abstract available

  42. ARNDTZ K, Hirschfield GM
    The Pathogenesis of Autoimmune Liver Disease.
    Dig Dis. 2016;34:327-33.
    PubMed     Abstract available

  43. DALTON HR, Webb GW, Norton BC, Woolson KL, et al
    Hepatitis E Virus: Time to Change the Textbooks.
    Dig Dis. 2016;34:308-16.
    PubMed     Abstract available

  44. BLUM HE
    History and Global Burden of Viral Hepatitis.
    Dig Dis. 2016;34:293-302.
    PubMed     Abstract available

  45. KOYAMA Y, Xu J, Liu X, Brenner DA, et al
    New Developments on the Treatment of Liver Fibrosis.
    Dig Dis. 2016;34:589-96.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.